Zanubrutinib is a BTKi approved by the FDA in 2023 for the treatment of CLL. Recognizing the important emerging role of BTKi as a therapeutic class in the treatment of CLL, the EML Committee advised that it would consider an application for zanubrutinib as therapeutic alternative for inclusion and recommended that MPP explore licensing opportunities to support affordable access. The primary patent on zanubrutinib was granted in few LMICs, including India, where it is expected to expire in 2034. Secondary patents on crystalline forms are expected to expire in 2037.

Patent & licence data in LMICs

Acronyms & abbreviations list